Catalyst Event
Alteogen Inc (196170) · Earnings Release
From KRX Bio Technology Transfer Index (KBIOTT)
3/22/2026, 12:00:00 AM
The announcement of record-high earnings for fiscal year 2025 on March 22, 2026, with revenue of 202.1 billion KRW, is expected to result in a >5% price impact, expected.
Korean Translation
2026년 3월 22일 발표 예정인 2025년 회계연도 사상 최대 실적은 매출 2,021억 원 달성에 따른 5% 이상의 주가 상승이 예상됨.
Related Recent Events
Hanmi Pharm Co Ltd (128940) · Other
Annual general shareholder meeting on 2026-03-31 to vote on the appointment of a new CEO and board members amid a management dispute; high impact estimated due to potential governance shift scheduled.
3/31/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Other
The 20th Annual General Shareholders' Meeting on March 31, 2026, to approve financial statements and appoint a new director (Low importance estimated as standard annual meetings without major corporate changes usually have minimal price impact) scheduled
3/31/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
The 25th Annual General Meeting of Shareholders is scheduled for March 26, 2026. Low importance is estimated as the agenda items are routine and unlikely to cause significant price volatility scheduled.
3/26/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Other
The 13th Annual General Meeting of Shareholders is scheduled.
3/26/2026, 12:00:00 AM
Alteogen Inc (196170) · Other
Alteogen's exclusive license agreement with Biogen for its ALT-B4 technology on March 25, 2026, is expected to have a >10% price impact due to the significant deal size of 867.6 billion KRW, scheduled.
3/25/2026, 12:00:00 AM
AprilBio Co Ltd (397030) · Other
The 13th Annual General Meeting of Shareholders was held on March 25, 2026. Resolutions passed included the approval of the 2025 financial statements, amendments to the articles of incorporation, and the granting of stock options.
3/25/2026, 12:00:00 AM